Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap |
|---|
| Enterprise Value |
|---|
| Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $43.73 | $2.54B | $2.07B | $718.95M | $60.82M | -$38.55M | -64.31x | 3.54x | 29.22x |
CP CPRX CATALYST PHARMACEUTICALS, INC. FY ended Apr 27, 2026 | $31.49 | $3.85B | $3.27B | $588.99M | $321.85M | $214.33M | 18.74x | 6.54x | 10.15x |
HR HRMY Harmony Biosciences Holdings, Inc. FY ended Feb 20, 2026 | $39.21 | $2.28B | $1.90B | $868.45M | $262.93M | $158.69M | 14.47x | 2.63x | 6.82x |
LL LLY ELI LILLY & Co FY ended Feb 09, 2026 | $1,174.61 | $1.11T | $1.16T | $65.18B | $28.02B | $20.64B | 51.18x | 16.96x | 40.66x |
IN INCY INCYTE CORP FY ended Feb 03, 2026 | $124.37 | $24.85B | $22.95B | $5.14B | $1.76B | $1.29B | 19.40x | 4.83x | 13.04x |
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $20.86 | $2.20B | $2.78B | $2.20B | -$686.34M | -$713.41M | -2.93x | 1.00x | — |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 21.49x | 5/6 | -$2.70B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 5.92x | 6/6 | $1.28B | $21.15 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 6.09x | 6/6 | -$1.34B | — | Target fundamentals do not produce a usable positive equity value. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $43.73 | $2.54B | $2.07B | $718.95M | $60.82M | -$38.55M | -64.31x | 3.54x | 29.22x |
CP CPRX CATALYST PHARMACEUTICALS, INC. FY ended Apr 27, 2026 | $31.49 | $3.85B | $3.27B | $588.99M | $321.85M | $214.33M | 18.74x | 6.54x | 10.15x |
HR HRMY Harmony Biosciences Holdings, Inc. FY ended Feb 20, 2026 | $39.21 | $2.28B | $1.90B | $868.45M | $262.93M | $158.69M | 14.47x | 2.63x | 6.82x |
LL LLY ELI LILLY & Co FY ended Feb 09, 2026 | $1,174.61 | $1.11T | $1.16T | $65.18B | $28.02B | $20.64B | 51.18x | 16.96x | 40.66x |
IN INCY INCYTE CORP FY ended Feb 03, 2026 | $124.37 | $24.85B | $22.95B | $5.14B | $1.76B | $1.29B | 19.40x | 4.83x | 13.04x |
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $20.86 | $2.20B | $2.78B | $2.20B | -$686.34M | -$713.41M | -2.93x | 1.00x | — |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 21.49x | 5/6 | -$2.70B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 5.92x | 6/6 | $1.28B | $21.15 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 6.09x | 6/6 | -$1.34B | — | Target fundamentals do not produce a usable positive equity value. |
